Andrew A Vernon
Overview
Explore the profile of Andrew A Vernon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
882
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Umucu E, Vernon A, Pan D, Qin S, Solis G, Campa R, et al.
Front Public Health
. 2025 Feb;
13:1538519.
PMID: 39995629
Background And Objective: Approximately 16% of the global population, or 1.3 billion individuals, live with disabilities, facing increased health risks. Despite international and national policies affirming the rights of persons...
2.
Tasneen R, Garcia A, Converse P, Zimmerman M, Dartois V, Kurbatova E, et al.
Antimicrob Agents Chemother
. 2022 Mar;
66(4):e0239821.
PMID: 35315690
A recent landmark trial showed a 4-month regimen of rifapentine, pyrazinamide, moxifloxacin, and isoniazid (PZMH) to be noninferior to the 6-month standard of care. Here, two murine models of tuberculosis...
3.
Lienhardt C, Nunn A, Chaisson R, Vernon A, Zignol M, Nahid P, et al.
PLoS Med
. 2020 Feb;
17(2):e1003059.
PMID: 32106220
Christian Lienhardt and co-authors discuss the conclusions of the PLOS Medicine Collection on advances in clinical trial design for development of new tuberculosis treatments.
4.
Lienhardt C, Vernon A, Cavaleri M, Nambiar S, Nahid P
PLoS Med
. 2019 Sep;
16(9):e1002915.
PMID: 31490921
Christian Lienhardt and colleagues discuss the importance of communication and coordination between regulators, researchers, and policy makers to ensure tuberculosis trials provide high-quality evidence for policy decisions.
5.
Njie G, Morris S, Yelk Woodruff R, Moro R, Vernon A, Borisov A
Am J Prev Med
. 2018 Jun;
55(2):244-252.
PMID: 29910114
Context: Latent tuberculosis infection diagnosis and treatment is a strategic priority for eliminating tuberculosis in the U.S. The Centers for Disease Control and Prevention has recommended the short-course regimen of...
6.
Vernon A, Villarino M
Clin Infect Dis
. 2012 Jan;
54(6):792-3.
PMID: 22267720
No abstract available.
7.
Burman W, Cotton M, Gibb D, Walker A, Vernon A, Donald P
PLoS Med
. 2008 Aug;
5(8):e176.
PMID: 18715115
No abstract available.
8.
Rosenthal I, Zhang M, Williams K, Peloquin C, Tyagi S, Vernon A, et al.
PLoS Med
. 2007 Dec;
4(12):e344.
PMID: 18092886
Background: Availability of an ultra-short-course drug regimen capable of curing patients with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because immediate prospects for novel treatment-shortening...
9.
Benator D, Weiner M, Burman W, Vernon A, Zhao Z, Khan A, et al.
Pharmacotherapy
. 2007 Jun;
27(6):793-800.
PMID: 17542762
Study Objective: To characterize the bidirectional interaction between twice-daily nelfinavir and twice-weekly rifabutin and isoniazid in patients with tuberculosis and human immunodeficiency virus (HIV) infection. Design: Prospective cohort study. Setting:...
10.
Rosenthal I, Williams K, Tyagi S, Peloquin C, Vernon A, Bishai W, et al.
Am J Respir Crit Care Med
. 2006 Apr;
174(1):94-101.
PMID: 16574936
Rationale: Recent studies have demonstrated that intermittent administration of rifamycin-based regimens results in higher rates of tuberculosis relapse and treatment failure compared with daily therapy. Twice-weekly treatment with rifampin, isoniazid,...